PHATHOM PHARMACEUTICALS INC. - COMMON STOCK

Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital

04 May 2022 08:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

03 May 2022 17:40:31 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors

26 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

01 Apr 2022 08:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

22 Mar 2022 08:02:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress

01 Mar 2022 16:04:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

09 Feb 2022 16:04:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference

23 Nov 2021 16:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences

12 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates

08 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Withdraws Public Offering

27 Oct 2021 21:47:20 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock

26 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting

24 Oct 2021 15:30:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial

18 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)

27 Sep 2021 08:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital

20 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection

08 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

31 Aug 2021 07:45:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones

10 Aug 2021 08:00:02 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.

05 Aug 2021 07:30:01 By Nasdaq GlobeNewswire